Data from our investigation may support the pathological heterogeneity of PD-CI in this group of patients, which is featured by the significantly elevated levels of T-tau and P-tau (S396) and the unchanged level of Aβ1–42. This evidence concerns the gene MAPT and Parkinson disease.